VolitionRx’s (VNRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX) in a report released on Thursday morning,Benzinga reports. D. Boral Capital currently has a $5.00 target price on the stock.

Several other equities research analysts have also issued reports on the stock. Benchmark restated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. StockNews.com assumed coverage on shares of VolitionRx in a research note on Thursday. They set a “sell” rating for the company.

VolitionRx Stock Performance

NYSE:VNRX opened at $0.54 on Thursday. The firm has a market cap of $50.44 million, a price-to-earnings ratio of -1.51 and a beta of 1.09. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.02. The firm has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $0.64.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp boosted its holdings in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares during the period. Two Sigma Securities LLC bought a new position in VolitionRx in the 4th quarter worth approximately $29,000. Millennium Management LLC bought a new position in VolitionRx in the 4th quarter worth approximately $36,000. Geode Capital Management LLC boosted its holdings in VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after buying an additional 95,900 shares during the period. Finally, Lagoda Investment Management L.P. boosted its holdings in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after buying an additional 1,481,000 shares during the period. 8.09% of the stock is owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.